Baseline Characteristics and Results of the Phase 2 COG1201 SHIMMER Study of Zervimesine (CT1812)

These data will allow comparison of the SHIMMER population to prior DLB study populations. SHIMMER results support the potential for zervimesine to slow clinical progression in patients with mild-to-moderate DLB. The robust therapeutic response observed across neuropsychiatric, cognitive, motor and functional measures is particularly encouraging. An analysis of participant characteristics will help guide recruitment in future clinical studies of zervimesine and its potential use to treat people with DLB. Cognition Therapeutics conducted COG1201 with University of Miami Miller School of Medicine and the Lewy Body Dementia Association under a grant from the National Institute of Aging (R01AG071643).